Intellia Therapeutics, Inc.
NTLA
$20.74
$0.723.60%
Headlines
4/26/2024
-
Tickeron - Stocks
4/25/2024
-
Zacks Investment Research
4/25/2024
-
Zacks Investment Research
4/25/2024
-
Tickeron - Technical Analysis
4/24/2024
-
Tickeron - Stocks
4/23/2024
-
Invezz News
4/23/2024
-
Tickeron - Stocks
4/20/2024
-
Ticker Report
4/20/2024
-
Zolmax
4/20/2024
-
Tickeron - Technical Analysis
4/19/2024
-
Stock Options Channel
4/19/2024
-
Tickeron - Stocks
4/19/2024
-
Zolmax
4/18/2024
-
Tickeron - Stocks
4/17/2024
-
Ticker Report
4/17/2024
-
Tickeron - Stocks
Sumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
4/17/2024
-
Zolmax
4/16/2024
-
Tickeron - Stocks
4/16/2024
-
Tickeron - Stocks
4/14/2024
-
Fool.com Headlines
4/12/2024
-
Fool.com Headlines
4/11/2024
-
Ticker Report
4/9/2024
-
TipRanks Financial Blog
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by China Universal Asset Management Co. Ltd.
4/5/2024
-
Ticker Report
Filings
Thursday, February 22, 2024
Sunday, December 31, 2023
Beginning of May (est)
Price History
Corporate Info
857 285 6200
40 Erie Street
Cambridge, MA 02139
Cambridge, MA 02139
Business Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial...
more